文献速递心脑血管急症

经颈动脉血运重建与经股动脉颈动脉支架置入术与卒中或死亡的关联

Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis.
PubMed 文献 · JAMA · 2019-01-01
一句话结论在颈动脉狭窄患者中,经颈动脉血运重建相较经股动脉颈动脉支架置入术与更低的卒中或死亡风险相关。

该研究为探索性倾向评分匹配分析,基于美国与加拿大前瞻性收集的血管质量倡议经颈动脉监测项目与颈动脉支架登记数据,纳入2016年9月至2019年4月因颈动脉狭窄接受经颈动脉血运重建或经股动脉颈动脉支架置入术的无症状与有症状患者。匹配后共3286对患者,经颈动脉组院内卒中或死亡1.6% vs 经股动脉组3.1%(绝对差-1.52%,95%CI -2.29%至-0.75%;RR 0.51,95%CI 0.37至0.72;P<.001),卒中1.3% vs 2.4%(RR 0.54,95%CI 0.38至0.79;P=.001),死亡0.4% vs 1.0%(RR 0.44,95%CI 0.23至0.82;P=.008)。1年同侧卒中或死亡经颈动脉组5.1% vs 经股动脉组9.6%(HR 0.52,95%CI 0.41至0.66;P<.001)。围手术期心肌梗死两组无统计学显著差异(0.2% vs 0.3%;RR 0.70,95%CI 0.27至1.84;P=.47)。经颈动脉组需要介入治疗的入路部位并发症风险更高(1.3% vs 0.8%;RR 1.63,95%CI 1.02至2.61;P=.04),而经股动脉组辐射和对比剂用量更多。

要点

  • 匹配后经颈动脉血运重建组院内卒中或死亡1.6%,经股动脉颈动脉支架置入术组3.1%(RR 0.51,95%CI 0.37至0.72;P<.001)。
  • 经颈动脉组1年同侧卒中或死亡5.1%,经股动脉组9.6%(HR 0.52,95%CI 0.41至0.66;P<.001)。
  • 围手术期心肌梗死两组无统计学显著差异(0.2% vs 0.3%;RR 0.70,95%CI 0.27至1.84;P=.47)。
  • 经颈动脉组需要介入治疗的入路部位并发症更高(1.3% vs 0.8%;RR 1.63,95%CI 1.02至2.61;P=.04)。
  • 经股动脉组中位透视时间16分钟(IQR 11至23)vs 经颈动脉组5分钟(IQR 3至7),中位对比剂用量80 mL(IQR 55至122)vs 30 mL(IQR 20至45),均P<.001。

适用人群与场景

  • 美国与加拿大因颈动脉狭窄接受经颈动脉血运重建或经股动脉颈动脉支架置入术的无症状与有症状患者。

研究设计与关键结果

  • 研究类型:探索性倾向评分匹配分析,基于血管质量倡议经颈动脉监测项目与颈动脉支架登记的前瞻性收集数据,研究期间经颈动脉血运重建5251例、经股动脉颈动脉支架置入术6640例,匹配后3286对。
  • 匹配后经颈动脉组平均(SD)年龄71.7(9.8)岁、女性35.7%;经股动脉组平均(SD)年龄71.6(9.3)岁、女性35.1%。
  • 院内卒中或死亡:经颈动脉组1.6% vs 经股动脉组3.1%,绝对差-1.52%(95%CI -2.29%至-0.75%),RR 0.51(95%CI 0.37至0.72),P<.001。
  • 卒中:经颈动脉组1.3% vs 经股动脉组2.4%,绝对差-1.10%(95%CI -1.79%至-0.41%),RR 0.54(95%CI 0.38至0.79),P=.001。
  • 死亡:经颈动脉组0.4% vs 经股动脉组1.0%,绝对差-0.55%(95%CI -0.98%至-0.11%),RR 0.44(95%CI 0.23至0.82),P=.008。
  • 围手术期心肌梗死:经颈动脉组0.2% vs 经股动脉组0.3%,绝对差-0.09%(95%CI -0.37%至0.19%),RR 0.70(95%CI 0.27至1.84),P=.47,无统计学显著差异。
  • 1年同侧卒中或死亡(Kaplan-Meier法):经颈动脉组5.1% vs 经股动脉组9.6%,HR 0.52(95%CI 0.41至0.66),P<.001。
  • 入路部位并发症需要介入治疗:经颈动脉组1.3% vs 经股动脉组0.8%,绝对差0.52%(95%CI -0.01%至1.04%),RR 1.63(95%CI 1.02至2.61),P=.04;中位透视时间经颈动脉组5分钟(IQR 3至7)vs 经股动脉组16分钟(IQR 11至23),中位对比剂用量经颈动脉组30 mL(IQR 20至45)vs 经股动脉组80 mL(IQR 55至122),均P<.001。

证据类型、等级与局限

  • 证据类型:探索性倾向评分匹配分析,基于前瞻性收集的登记数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于因颈动脉狭窄接受治疗的患者,经颈动脉血运重建相较经股动脉颈动脉支架置入术与更低的卒中或死亡风险相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Several trials have observed higher rates of perioperative stroke following transfemoral carotid artery stenting compared with carotid endarterectomy. Transcarotid artery revascularization with flow reversal was recently introduced for carotid stenting. This technique was developed to decrease stroke risk seen with the transfemoral approach; however, its outcomes, compared with transfemoral carotid artery stenting, are not well characterized.

OBJECTIVE: To compare outcomes associated with transcarotid artery revascularization and transfemoral carotid artery stenting.

DESIGN, SETTING, AND PARTICIPANTS: Exploratory propensity score-matched analysis of prospectively collected data from the Vascular Quality Initiative Transcarotid Artery Surveillance Project and Carotid Stent Registry of asymptomatic and symptomatic patients in the United States and Canada undergoing transcarotid artery revascularization and transfemoral carotid artery stenting for carotid artery stenosis, from September 2016 to April 2019. The final date for follow-up was May 29, 2019.

EXPOSURES: Transcarotid artery revascularization vs transfemoral carotid artery stenting.

MAIN OUTCOMES AND MEASURES: Outcomes included a composite end point of in-hospital stroke or death, stroke, death, myocardial infarction, as well as ipsilateral stroke or death at 1 year. In-hospital stroke was defined as ipsilateral or contralateral, cortical or vertebrobasilar, and ischemic or hemorrhagic stroke. Death was all-cause mortality.

RESULTS: During the study period, 5251 patients underwent transcarotid artery revascularization and 6640 patients underwent transfemoral carotid artery stenting. After matching, 3286 pairs of patients who underwent transcarotid artery revascularization or transfemoral carotid artery stenting were identified (transcarotid approach: mean [SD] age, 71.7 [9.8] years; 35.7% women; transfemoral approach: mean [SD] age, 71.6 [9.3] years; 35.1% women). Transcarotid artery revascularization was associated with a lower risk of in-hospital stroke or death (1.6% vs 3.1%; absolute difference, -1.52% [95% CI, -2.29% to -0.75%]; relative risk [RR], 0.51 [95% CI, 0.37 to 0.72]; P < .001), stroke (1.3% vs 2.4%; absolute difference, -1.10% [95% CI, -1.79% to -0.41%]; RR, 0.54 [95% CI, 0.38 to 0.79]; P = .001), and death (0.4% vs 1.0%; absolute difference, -0.55% [95% CI, -0.98% to -0.11%]; RR, 0.44 [95% CI, 0.23 to 0.82]; P = .008). There was no statistically significant difference in the risk of perioperative myocardial infarction between the 2 cohorts (0.2% for transcarotid vs 0.3% for the transfemoral approach; absolute difference, -0.09% [95% CI, -0.37% to 0.19%]; RR, 0.70 [95% CI, 0.27 to 1.84]; P = .47). At 1 year using Kaplan-Meier life-table estimation, the transcarotid approach was associated with a lower risk of ipsilateral stroke or death (5.1% vs 9.6%; hazard ratio, 0.52 [95% CI, 0.41 to 0.66]; P < .001). Transcarotid artery revascularization was associated with higher risk of access site complication resulting in interventional treatment (1.3% vs 0.8%; absolute difference, 0.52% [95% CI, -0.01% to 1.04%]; RR, 1.63 [95% CI, 1.02 to 2.61]; P = .04), whereas transfemoral carotid artery stenting was associated with more radiation (median fluoroscopy time, 5 minutes [interquartile range {IQR}, 3 to 7] vs 16 minutes [IQR, 11 to 23]; P < .001) and more contrast (median contrast used, 30 mL [IQR, 20 to 45] vs 80 mL [IQR, 55 to 122]; P < .001).

CONCLUSIONS AND RELEVANCE: Among patients undergoing treatment for carotid stenosis, transcarotid artery revascularization, compared with transfemoral carotid artery stenting, was significantly associated with a lower risk of stroke or death.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Schermerhorn ML, Liang P, Eldrup-Jorgensen J, et al. Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis. JAMA. 2019. PMID: 31846015. doi:10.1001/jama.2019.18441

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。